Mon panier

Postfusion glycoprotein F0/post-F protein (RSV)

Postfusion glycoprotein F0/post-F protein (RSV) Liste de produits

  • Attribut

    Protein (2)Antibody (2)

  • Bibliothèque de produits

    En ligne (4)

  • Espèces

    Human respiratory syncytial virus A (strain A2) (1)Human respiratory syncytial virus B (strain B1) (1)Mouse (2)

  • Étiquette

    His Tag (2)- (2)

  • Marqueur

    Unconjugated (4)

Numéro de produitEspècesSystème d'expressionDescription du produitStructure protéiquePuretéCaractéristiquesPré-commande/Commande
HOT
RSV-M662
Mouse
HEK293
Monoclonal Anti-RSV-post-F0 specific Antibody, Human IgG1 (1A2D9D8) (MALS verified) Ajouter au panier
HOT
RSF-V52H6
Human respiratory syncytial virus A (strain A2)
HEK293
HRSV (A) Post-fusion glycoprotein F0, His Tag (MALS verified) Ajouter au panier
HOT
RSF-V52H9
Human respiratory syncytial virus B (strain B1)
HEK293
HRSV (B) Post-fusion glycoprotein F0, His Tag (MALS verified) Ajouter au panier
RSV-Y180
Mouse
Hybridoma
Monoclonal Anti-RSV-post-F0 specific Antibody, Mouse IgG1 (1A2D9D8) (MALS verified) Ajouter au panier
Quantité totale4
  • 1

Postfusion glycoprotein F0/post-F protein (RSV)Contexte de la molécule

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
RGN-259Fx peptide; TB4 16-38; RGN-457; Thymosin beta 4-16-38; Thymosin B4; RGN-352; RGN-259; RGN-137; Tβ4; TB4; GBT-201; GBT-101; Thymosin beta4Phase 3 ClinicalNational Institutes Of HealthKeratitis; Myocardial Ischemia; ST Elevation Myocardial Infarction; Myocardial Infarction; Graft vs Host Disease; Sjogren's Syndrome; Dry Eye Syndromes; Epidermolysis Bullosa; Pressure Ulcer; Epidermolysis Bullosa, Junctional; Varicose Ulcer; Diabetes Mellitus; Epidermolysis Bullosa Dystrophica
Details
FasinumabSAR-164877; MT-5547; R-475; REGN-475Phase 3 ClinicalAbdominal Pain; Sciatica; Osteoarthritis, Knee; Back Pain; Osteoarthritis; Low Back Pain; Osteoarthritis, Hip
Details
MEDI-7352MEDI-7352Phase 2 ClinicalMedimmuneChronic Pain; Diabetic Neuropathies; Osteoarthritis, Knee
Details
N-HexacosanoltCFA15; TAC-302Phase 2 ClinicalMeiji Seika Pharma Co LtdUrinary Bladder, Underactive; Urinary Bladder, Overactive
Details
Antibodies to humanized nerve growth factor(Shenyang Sunshine Pharmaceutical)Phase 2 ClinicalShenyang Sunshine Pharmaceutical Co LtdBone metastases; Cancer Pain
Details
EP-9001AEP-9001APhase 2 ClinicalChengdu Youluo Biotechnology Co LtdBone metastases; Cancer Pain; Pain
Details
DS-002DS-002Phase 2 ClinicalDartsbio Pharmaceuticals LtdPain; Cancer Pain
Details
AtinumabNG-101; ATI-355Phase 2 ClinicalNovartis Pharma AgSpinal Cord Injuries; Gastroparesis; Diabetic Gastroparesis
Details
SSS-40SSS-40; SSS-40-anti-NGF Ab; SSS40 anti-NGF AbPhase 1 Clinical3sbio IncCancer Pain; Bone Neoplasms; Osteoarthritis
Details
LuvagrobartAK-115Phase 1 ClinicalZhongshan Akeso Biopharma Co LtdPain; Cancer Pain
Details
TNM-009TNM-009; TNM009Phase 1 ClinicalZhuhai Trinomab Pharmaceutical Co LtdCancer Pain; Pain
Details
SMR-7694SMR-7694; SMR7694Phase 1 ClinicalSinobioway Biomedicine Co LtdOsteoarthritis
Details
Neuroregenerative agents (iNtRON Biotechnology)ClinicalIntron BiotechnologyNervous System Diseases
Details
  • Liste de produits
  • Informations sur les médicaments cliniques